Chemotherapy practices and perspectives in invasive bladder cancer

Expert Review of Anticancer Therapy

Volumn 6, Issue 10, 2006, Pages 1473-1482

  Flechon, Aude ^a   Droz, Jean Pierre ^a  

^a CENTRE LÉON BÉRARD   (France)

Author keywords

Adjuvant; Bladder cancer; Chemotherapy; Cisplatin; Epidermal growth factor receptor; Gemcitabine; Neoadjuvant; Paclitaxel; Phase III trial; Targeted drugs

Indexed keywords

4 N ACETYLDINALINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE RECEPTOR; DEHYDRODIDEMNIN B; DNA; DOCETAXEL; DOXORUBICIN; GALLIUM NITRATE; GENTAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; IFOSFAMIDE; LONAFARNIB; METHOTREXATE; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; OXALIPLATIN; PACLITAXEL; PROTEIN P14ARF; PROTEIN P53; SORAFENIB; SUBEROYLANILIDE HYDROXAMIC ACID; TIPIFARNIB; TRASTUZUMAB; UNINDEXED DRUG; VINBLASTINE; VINFLUNINE;

ADVANCED CANCER; ANEMIA; BLADDER CANCER; BLADDER CARCINOGENESIS; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER INFILTRATION; CANCER INVASION; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CYSTECTOMY; DNA METHYLATION; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG RESEARCH; DRUG TARGETING; FEBRILE NEUTROPENIA; HUMAN; KIDNEY DYSFUNCTION; META ANALYSIS; MOLECULAR MECHANICS; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUTROPENIA; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 33750713078     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.10.1473     Document Type: Review

References (69)

1. Shipley WU, Kaufman DS, McDougal WS, Dahl DD, Michaelson MD, Zietman AL. Cancer of the bladder, ureter and renal pelvis. In: Cancer: Principles and Practice of Oncology 7th Edition. De Vita VT, Hellman S, Rosenberg SA (Eds). Lippincott Williams and Wilkins, Philadelphia, USA, 1178-1191 (2005).
2. Amin MB, Murphy WM, Reuter VE et al. A symposium on controversies in the pathology of transitional cell carcinomas of the urinary bladder. Part I. Anat. Pathol. 1; 1-39 (1996).
3. American Joint Committee on Cancer. Cancer Staging Manual, 6th edition. Springer-Verlag, NY, USA (2002).
4. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann. Oncol. 16, 481-488 (2005).
5. Al-Sukhun S, Hussain M. Molecular biology of transitional cell carcinoma. Crit. Rev. Oncol. Hematol. 47, 181-193 (2003).
6. Chatterjee SJ, Datar R, Youssefzadeh D et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J. Clin. Oncol. 22, 1007-1013 (2004).
7. Le Frere-Belda MA, Gil Diez de Medina S, Daher A et al. Profiles of the 2 INK4a gene products, p16 and p14ARF, in human reference urothelium and bladder carcinomas, according to pRb and p53 protein status. Hum. Pathol. 35, 817-824 (2004).
8. van Rhijn BW, Vis AN, van der Kwast TH et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathological grade for the prediction of clinical outcome. J. Clin. Oncol. 21, 1912-1921 (2003).
9. Basso U, Bassi P, Sava T, Monfardini S. Management of muscle-invasive bladder cancer in the elderly. Expert Rev. Anticancer Ther. 4, 1017-1035 (2004).
10. Terret C. Management and geriatric assessment of cancer in the elderly. Expert Rev. Anticancer Ther. 4, 469-475 (2004).
11. Stein JP, Skinner DG. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J. Urol. 24(3), 296-304 (2006).
12. Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19, 666-675 (2001).
13. Coppin CM, Gospodarowicz MK, James K et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 14, 2901-2907 (1996).
14. Shipley WU, Kaufman DS, Zehr E et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 60, 62-67 (2002).
15. Shipley WU, Winter KA, Kaufman D et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J. Clin. Oncol. 16, 3576-3583 (1998).
16. Small EJ, Halabi S, Dalbagni G et al. Overview of bladder cancer trials in the Cancer and Leukemia Group B. Cancer 97, 2090-2098 (2003).
17. Blumenreich MS, Yagoda A, Natale RB, Watson RC. Phase II trial of vinblastine sulfate for metastatic urothelial tract tumors. Cancer 50, 435-438 (1982).
18. Natale RB, Yagoda A, Watson RC, Whitmore WF, Blumenreich M, Braun DW Jr. Methotrexate: an active drug in bladder cancer. Cancer 47, 1246-1250 (1981).
19. Ahmed T, Yagoda A, Needles B, Scher HI, Watson RC, Geller N. Vinblastine and methotrexate for advanced bladder cancer. J. Urol. 133, 602-604 (1985).
20. Merrin C. Treatment of advanced bladder cancer with cis-diamminedichloroplatinum (II NSC 119875): a pilot study. J. Urol. 119, 493-495 (1978).
21. Yagoda A, Watson RC, Whitmore WF, Grabstald H, Middleman MP, Krakoff IH. Adriamycin in advanced urinary tract cancer: experience in 42 patients and review of the literature. Cancer 39, 279-285 (1977).
22. Sternberg CN, Yagoda A, Scher HI et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64, 2448-2458 (1989).
23. Harker WG, Meyers FJ, Freiha FS et al. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J. Clin. Oncol. 3, 1463-1470 (1985).
24. Gabrilove JL, Jakubowski A, Scher H et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N. Engl. J. Med. 318, 1414-1422 (1988).
25. Sternberg CN, de Mulder PH, van Oosterom AT, Fossa SD, Giannarelli D, Soedirman JR. Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors. Ann. Oncol. 4, 403-407 (1993).
26. Loehrer PJ Sr, Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 10, 1066-1073 (1992).
27. Saxman SB, Propert KJ, Einhorn LH et al. Long-term follow-up of a Phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 15, 2564-2569 (1997).
28. Logothetis CJ, Dexeus FH, Finn L et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Clin. Oncol. 8, 1050-1055 (1990).
29. Sternberg CN, de Mulder PH, Schornagel JH et al. Randomized Phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J. Clin. Oncol. 19, 2638-2646 (2001).
30. Geller NL, Sternberg CN, Penenberg D, et al. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer 67, 1525-1531 (1991).
31. Miller RS, Freiha FS, Reese JH, Ozen H, Torti FM. Cisplatin, methotrexate and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urothelium. J. Urol. 150, 65-69 (1993).
32. Sweeney P, Millikan R, Donat et al. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J. Urol. 169, 2113-2117 (2003).
33. von der Maase H. Gemcitabine in locally advanced and/or metastatic bladder cancer. Crit. Rev. Oncol. Hematol. 34, 175-183 (2000).
34. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, ulticenter, Phase III study. J. Clin. Oncol. 18, 3068-3077 (2000).
35. von der Maase H, Sengelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methorexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 23, 4602-4608 (2005).
36. Bajorin DF. Paclitaxel in the treatment of advanced urothelial cancer. Oncology 14, 43-52 (2000).
37. Dreicer R, Manola J, Roth BJ et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 100, 1639-1645 (2004).
38. Bellmunt J, Albanell J, Paz-Ares L et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a Phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 95, 751-757 (2002).
39. Lorusso V, Crucitta E, Silvestris N et al. Randomised, open-label, Phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium. Oncol. Rep. 13, 283-287 (2005).
40. Hussain M, Vaishampayan U, Du W, Redman B, Smith DC. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J. Clin. Oncol. 19, 2527-2533 (2001).
41. Hainsworth JD, Meluch AA, Litchy S et al. Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer 103, 2298-2303 (2005).
42. Dodd PM, McCaffrey JA, Hilton S et al. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. J. Clin. Oncol. 18, 840-846 (2000).
43. Bajorin DF, McCaffrey JA, Dodd PM et al. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a Phase II trial evaluating two dosing schedules. Cancer 88, 1671-1678 (2000).
44. Galsky MD, Iasonos S, Mironov J et al. Prospective trial of Ifosfamide, Paclitaxel and Cisplatin (ITP) in patients with advanced non-transitional cell carcinomas of the urothelial tract (Abstract 4542). Proc. Am. Soc. Clin. Oncol. 24, S227 (2006).
45. Dimopoulos MA, Bakoyannis C, Georgoulias V et al. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter Phase II study of the Hellenic Cooperative Oncology Group. Ann. Oncol. 10, 1385-1388 (1999).
46. Bamias A, Aravantinos G, Bafaloukos D et al. Docetaxel and cisplatin versus M-VAC in advanced urothelial carcinoma: a multicenter, randomized, Phase III study conducted by the Hellenic Cooperative Oncology Group. (abstr 1541). Proc. Am. Soc. Clin. Oncol. 22, S302 (2003).
47. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and met-analysis of individual patient data advanced bladder cancer (ABC) met-analysis collaboration. Eur. Urol. 48, 202-205 (2005).
48. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 354, 533-540 (1999).
49. Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859-866 (2003).
50. Smith DC, Mackler NJ, Hussain MH et al. Neoadjuvant paclitaxel, Gemcitabine and Carboplatin in patients with locally advanced transitional cell carcinoma of the bladder: a final report. Proc. Am. Soc. Clin. Oncol. 24, S226 (2006) (Abstract 4541).
51. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur. Urol. 48, 189-199 (2005).
52. Esrig D, Elmajian D, Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med. 331, 1259-1264 (1994).
53. Duncan L, Heathcote J, Djurdjev O, Levin A. Screening for renal disease using serum creatinine: who are we missing? Nephrol. Dial. Transplant. 16, 1042-1046 (2001).
54. Terret C, Albrand G, Droz JP. Geriatric assessment in elderly patients with prostate cancer. Clin. Prostate Cancer 2, 236-240 (2004).
55. Bamias A, Efstathiou E, Moulopoulos LA et al. The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. Ann. Oncol. 16, 307-313 (2005).
56. Bamias A, Moulopoulos LA, Koutras A et al. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group. Cancer 106, 297-303 (2006).
57. C. Theodore, F. Bidault, K. Fizazi et al. A Phase II monocentric study of Oxaliplatin (Ox) in combination with Gemcitabine (Gem) (GEMOX) in patients (pts) with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract.(Abstract 4595) Proc. Am. Soc. Clin. Oncol. 23, S221 (2005).
58. Castagneto B, Zai S, Marenco D et al. Single-agent gemcitabine in previously untreated elderly patients with advanced bladder carcinoma: response to treatment and correlation with the comprehensive geriatric assessment. Oncology 67, 27-32 (2004).
59. Li J, Juliar B, Yiannoutsos C et al. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a Phase II Hoosier Oncology Group study. J. Clin. Oncol. 23, 1185-1191 (2005).
60. Sternberg CN, Calabro F, Pizzocaro G, Marini L, Schnetzer S, Sella A. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 92, 2993-2998 (2001).
61. Sternberg CN, Pansadoro V, Calabro F et al. Can patient selection for bladder preservation be based on response to chemotherapy? Cancer 97, 1644-1652 (2003).
62. David KA, Nanus DM, Milowsky MI et al. Perioperative chemotherapy treatment patterns in stage III transitional cell carcinoma (1998-2003): a report from the National cancer Data Base (Abstract 4540). Proc. Am. Soc. Clin. Oncol. 24, S226 (2006).
63. Wolff EM, Liang G, Jones PA. Mechanisms of disease: genetic and epigenetic alterations that drive bladder cancer. Nat. Clin. Pract. Urol. 10, 502-510 (2005).
64. Pauer LR, Olivares J, Cunningham C et al. Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Invest. 2, 886-896 (2004).
65. Boucher T, Patton R, Seymour L. A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. Urol. Oncol. 23, 143-149 (2005).
66. Rosenberg JE, von der Maase H, Seigne JD et al. A Phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma. Cancer 103, 2035-2041 (2005).
67. Chakravarti A, Winter K, Wu Cl et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. 62, 309-317 (2005).
68. Lashinger LM, Zhu K, Williams SA, Shrader M, Dinney CP, McConkey DJ. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res. 65, 4902-4908 (2005).
69. Zi X, Simoneau AR, Flavokawain A. A novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice. Cancer Res. 65, 3479-3486 (2005).